Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC

Name: Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC
Uploaded: 2016-10-25T04:00:54.000Z
Description: Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses the FDA approval of pembrolizumab (Keytruda) in the frontline setting for patients with non–small cell lung cancer (NSCLC).

October 25, 2016

Heather A. Wakelee, MD, FASCO

Video

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses the FDA approval of pembrolizumab (Keytruda) in the frontline setting for patients with non–small cell lung cancer (NSCLC).